About Multi-action UltraSal TM–ER

Elorac Direct Savings flagClinical trials show salicylic acid is the treatment choice with the best evidence supporting its effectiveness in removing common and plantar warts.1

UltraSal-ER (28.5% salicylic acid extended release) provides a unique easy-to-apply formulation that helps get rid of unsightly warts.2

Long Acting

UltraSal-ER uses a special, patented, sub-micron encapsulated delivery system that penetrates the skin and delivers wart-fighting action long after it is applied.3 This extended-release delivery also minimizes irritation and maintains an optimal pH of the skin.2

Strongest Formula

UltraSal-ER is the strongest prescription salicylic acid wart treatment available.3 This power helps the formula effectively loosen and peel away the wart-infected skin.2 There is no generic or branded equivalent for UltraSal-ER.

Antiviral Solution

UltraSal-ER works against the virus that causes warts. It is also designed to help reduce risk of skin reinfection at the wart site and prevent the virus from contaminating the product, with normal use.2

Convenient

UltraSal-ER has a tailored brush built right into the bottle cap for neat and precise application. Once applied, the anti-viral solution covers warts with a protective, water-resistant seal so that no bandage is needed.2

See full Prescribing Information for UltraSal-ER (28.5% salicylic acid extended release). Talk to your healthcare professional for more information.

Uses

UltraSal-ER is used for the topical treatment and removal of common warts and plantar warts.

Important Safety Information

For topical use only. Not for ophthalmic, oral, or intravaginal use. A localized irritant reaction may occur if UltraSal-ER is applied to the normal skin surrounding the wart.

Patients with diabetes or impaired blood circulation should not use UltraSal-ER. UltraSal-ER also should not be used on moles, birthmarks, and unusual warts with hair growing from them, or warts on the face.

References: 1. Mulhem E, Pinelis S. Treatment of nongenital cutaneous warts. Am Fam Physician. 2011; 84(3):288-293,296. 2. UltraSalâ„¢-ER (28.5% salicylic acid extended release) prescribing information, Elorac, Inc., January 2014. 3. Data on File, Elorac, Inc. Vernon Hills, IL.